clinical study of Nagabala Arjunadi Yoga in the management of Post Myocardial Infarction( Hridroga)

Efficacy of Nagabala -Arjunadi Yoga in the management of Post- Myocardial Infarction (Hridroga) as an add-on to the conventional treatment- A randomized standard controlled clinical trial - Interventional

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/03/032088

Enrollment

Registered

2021-03-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I22- Subsequent ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction Health Condition 2: I229- Subsequent ST elevation (STEMI) myocardial infarction of unspecified site

Interventions

Intervention1: Nagabala- Arjunadi Yoga: In Group A, Nagabala-Arjunadi yoga will be given to the patients for a period of 2 months Control Intervention1: standard conventional treatment: Group B, 1.A

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed as having recent Myocardial Infarction, after 2 weeks of occurrence of the event upto 6 months of the event and under the standard conventional treatment will only be recruited into the present study. 2. Patients within the age limit of 30-65 years of either sex 3. Patients willing to sign the consent

Exclusion criteria

Exclusion criteria: Acute MI due to non â?? atheromatous causes 2. AMI associated with any other heart disease like valvular heart disease or congenital heart disease 3. Patients with ejection fraction less than 35% 4. Patients with Recurrent MI 5. Pateints who had underwent Coronary artery bypass grafting 6. Post MI (within 2 weeks) or Unstable Angina 7. Patients with severe or uncontrolled Liver or Kidney disorders or malignant hypertension or COPD patients 8. Patients with severe / serious arrhythmias or presenting with congestive cardiac failure or ascitis

Design outcomes

Primary

Measure	Time frame
It is expected that the trial drug will improve the Post â?? MI ischemic outcome of the patient in terms of fatigue, angina severity and frequency, dyspnoea, functional capacity and LV functionTimepoint: 2 months	—

Secondary

Measure	Time frame
The trial drug will have a positive effect on health related quality of life in the post MI patientsTimepoint: 2 months	—

Countries

India

Contacts

Public ContactDr Mandip Goyal

ITRA, jamnagar

mandipgoyal22@gmail.com9427572306

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026